Person:
Nee, Judy

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Nee

First Name

Judy

Name

Nee, Judy
Author's Publications: search.filters.isAuthorOfPublication.7fb6c345-9207-4bf6-a380-7febe8a92e64

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial
    (BioMed Central, 2017) Ballou, Sarah; Kaptchuk, Ted; Hirsch, William; Nee, Judy; Iturrino, Johanna; Hall, Kathryn; Kelley, John; Cheng, Vivian; Kirsch, Irving; Jacobson, Eric; Conboy, Lisa; Lembo, Anthony; Davis, Roger
    Background: Placebo medications, by definition, are composed of inactive ingredients that have no physiological effect on symptoms. Nonetheless, administration of placebo in randomized controlled trials (RCTs) and in clinical settings has been demonstrated to have significant impact on many physical and psychological complaints. Until recently, conventional wisdom has suggested that patients must believe that placebo pills actually contain (or, at least, might possibly contain) active medication in order to elicit a response to placebo. However, several recent RCTs, including patients with irritable bowel syndrome (IBS), chronic low back pain, and episodic migraine, have demonstrated that individuals receiving open-label placebo (OLP) can still experience symptomatic improvement and benefit from honestly described placebo treatment. Methods and design This paper describes an innovative multidisciplinary trial design (n = 280) that attempts to replicate and expand upon an earlier IBS OLP study. The current study will compare OLP to double-blind placebo (DBP) administration which is made possible by including a nested, double-blind RCT comparing DBP and peppermint oil. The study also examines possible genetic and psychological predictors of OLP and seeks to better understand participants’ experiences with OLP and DBP through a series of extensive interviews with a randomly selected subgroup. Discussion OLP treatment is a novel strategy for ethically harnessing placebo effects. It has potential to re-frame theories of placebo and to influence how physicians can optimize watch-and-wait strategies for common, subjective symptoms. The current study aims to dramatically expand what we know about OLP by comparing, for the first time, OLP and DBP administration. Adopting a unique, multidisciplinary approach, the study also explores genetic, psychological and experiential dimensions of OLP. The paper ends with an extensive discussion of the “culture” of the trial as well as potential mechanisms of OLP and ethical implications. Trial registration ClinicalTrials.gov, identifier: NCT02802241. Registered on 14 June 2016. Electronic supplementary material The online version of this article (doi:10.1186/s13063-017-1964-x) contains supplementary material, which is available to authorized users.
  • Thumbnail Image
    Publication
    Optimizing the Care and Health of Women with Inflammatory Bowel Disease
    (Hindawi Publishing Corporation, 2015) Nee, Judy; Feuerstein, Joseph
    Inflammatory bowel disease (IBD) including both ulcerative colitis and Crohn's disease is increasing worldwide. Although diagnosis is equally found in men and women, the chronicity of IBD poses a unique impact on the milestones of a woman's life. As the gastroenterologist becomes increasingly important in the health maintenance of patients with IBD, this review stresses the unique gender issues in women with IBD related to menstruation, cervical cancer, sexual health, contraception, and menopause that may affect the course of disease, treatment decisions, and quality of life.